Vishal Mega Mart, Sai Life Sciences: Shares Worth Rs 39,000 Crore To Exit Lock-Ins On Tuesday
Shares worth over Rs 39,385 crore of Vishal Mega Mart Ltd. and Sai Life Sciences Ltd. are set to exit their respective lock-in periods on Tuesday.
As much as 56% equity of Vishal Mega Mart and 48% equity of Sai Life Sciences is set to become eligible for trade as the six-month lock-in period ends for shareholders, as per Nuvama's report.
As many as 254.2 crore shares of Vishal Mega Mart worth Rs 31,775 crore will become free to trade.
The shareholding valued at Rs 31,775 crore, is nearly four times more than the IPO issue size of Rs 8,000 crore. Currently, the company has Rs 14,131 crore in free float market capitalisation for public to trade.
As much as 48% of the equity or 10 crore shares worth Rs 7,610 crore will become free to trade for Sai Life Sciences.
Sai life Sciences' shareholding valued at Rs 7,610 crore is 2.5 times more than the IPO issue size. Currently, Rs 4,900 crore free float market capitalisation is available for public to trade.
How Share Prices Have Moved
Vishal Mega Mart made a strong debut on the bourses, listing at Rs 104 against its IPO price of Rs 78. The stock surged to an all-time high of Rs 135 before settling around Rs 125 currently, down about 7.5% from its peak but still delivering an impressive 60% return over the IPO price. The performance reflects strong investor interest and confidence in stock.
Sai Life Sciences has delivered a robust post-IPO performance, listing at Rs 764 compared to its IPO price of Rs 549. The stock reached an all-time high of Rs 808 and is currently trading at Rs 763, just 5.56% below its all-time high. Despite a slight pullback, it remains 38% above its issue price, reflecting strong investor confidence in the company's position.
Analysts' View
Out of nine analysts tracking Vishal Mega Mart, seven recommend a 'Buy', one recommends a 'Hold', and one 'Sell'. Morgan Stanley has the most bullish target at Rs 161, while Bernstein has a bearish view with a Rs 90 target.
Meanwhile, Sai Life Sciences is being tracked by four analysts, with two with a 'Buy' ,one 'Hold', and one ‘Sell' rating. Morgan Stanley again leads to the upside with a target price of Rs 911.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
-
India Is Going Abroad For Critical Minerals. But It May Take Years To Pay Off | The Reason Why
Although India's steps are in the right direction, they remain modest compared with India's growing dependence.
